TacticScaleWhat Cencora Does & How It Makes Money (COR)
Updated October 2026 · reflects Cencora's latest reported financials
Major drug wholesaler distributing medicines to pharmacies and hospitals worldwide. It earns a small margin on the large volume of pharmaceuticals and healthcare products it buys from manufacturers and resells to pharmacies, hospitals and clinics.
How Cencora makes money
It earns a small margin on the large volume of pharmaceuticals and healthcare products it buys from manufacturers and resells to pharmacies, hospitals and clinics. It adds fee-based revenue from services to drug makers and providers, such as commercialization support, data analytics, logistics, consulting and software.
What Cencora does
Cencora, formerly AmerisourceBergen and founded in 1871, is one of the key intermediaries in the pharmaceutical supply chain. Its U.S. Healthcare Solutions segment distributes branded, generic and specialty drugs, vaccines, plasma products and over-the-counter goods to hospitals, retail and mail-order pharmacies, clinics and long-term care sites. It also sells animal health products and provides services to drug makers and providers, including consulting, packaging, software, data analytics and clinical trial and commercialization support. The International Healthcare Solutions segment runs pharmaceutical wholesale operations outside the U.S. and offers global commercialization services and specialty transportation for biopharma companies. Cencora sells in very large volumes at thin margins, and its specialty and service businesses add to that core distribution revenue. The company is headquartered in Conshohocken, Pennsylvania.
Products & services
- Pharmaceutical wholesale distribution
- Specialty drugs, vaccines and plasma products
- Oncology physician services
- Animal health products
- Clinical trial and commercialization services
- Specialty biopharma logistics
What is Cencora worth?
On an owner-earnings DCF, Cencora's most-likely value is about $569 versus a recent price near $324 (76% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$246) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Centene (CNC) · McKesson (MCK) · Cardinal Health (CAH) · C.Q. Pharmaceutical Holding (000950.SZ) · China National Accord Medicines (000028.SZ)